Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other 3Gynecologic 1

Conditions

Constipation 3Neoplasms 2Intestinal Diseases 2Opioid-Induced Constipation 1Cancer Pain 1

Interventions

Radiotherapy 5Surveys and Questionnaires 4Cisplatin 4angiotensin I (1-7) 3alvimopan 3Radiation 3Injections 3Water 2Vitamin D 2Tirzepatide 2RRx-001 2Mouthwashes 2Metformin 2Interleukin 1 Receptor Antagonist Protein 2High-Intensity Focused Ultrasound Ablation 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Calcium Dobesilate 2Amifostine 2Acetylcysteine 2tempol 1peppermint oil 1pegfilgrastim 1naloxegol 1methylnaltrexone 1methyl N-acetylsibirosaminide 1linaclotide 1licogliflozin 1kang-lai-te 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × alvimopan × Other × Clear all
NCT00101998 2017-08-30

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
233 enrolled
Other

Cancer Pain, Constipation, Intestinal Diseases

NCT00135577 2015-09-02

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
67 enrolled
Other

Opioid-Induced Constipation, Constipation, Intestinal Diseases, Neoplasms

NCT00331045 2015-09-02

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
21 enrolled
Other

Constipation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡